Phio Pharmaceuticals Corp. (PHIO:NASDAQ) Annual Reports & Investor Relations Material

Overview

Phio Pharmaceuticals Corp, a US-based biotech firm, is making significant strides in the development of immuno-oncology therapeutics. The company's portfolio includes PH-762, which activates immune cells to recognize and destroy cancer cells through the reduction of the checkpoint protein PD-1, and PH-894, a treatment that silences the epigenetic protein BRD4, which regulates gene expression for use in T and tumor cells. Additionally, Phio Pharmaceuticals Corp is developing PH-804, which targets the immune receptor TIGIT, a suppressive checkpoint protein found on T cells and natural killer cells. Founded in 2011 and previously known as RXi Pharmaceuticals Corporation, the company adopted its current name in November 2018. Its headquarters are located in Marlborough, Massachusetts.

Frequently Asked Questions

What is Phio Pharmaceuticals Corp.'s ticker?

Phio Pharmaceuticals Corp.'s ticker is PHIO

What exchange is Phio Pharmaceuticals Corp. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Phio Pharmaceuticals Corp.'s headquarters?

They are based in Marlborough, Massachusetts

How many employees does Phio Pharmaceuticals Corp. have?

There are 11-50 employees working at Phio Pharmaceuticals Corp.

What is Phio Pharmaceuticals Corp.'s website?

It is http://www.phiopharma.com/

What type of sector is Phio Pharmaceuticals Corp.?

Phio Pharmaceuticals Corp. is in the Healthcare sector

What type of industry is Phio Pharmaceuticals Corp.?

Phio Pharmaceuticals Corp. is in the Biotechnology industry

Who are Phio Pharmaceuticals Corp.'s peers and competitors?

The following five companies are Phio Pharmaceuticals Corp.'s industry peers:

- Personalis

- KemPharm Inc

- Aptinyx

- Sunesis Pharmaceuticals, Inc.

- Cellectar Biosciences, Inc.